Form 4: Cititus Oncology Director Acquires 125,000 Stock Options

Director Dennis M. McGrath acquired 125,000 stock options in Citius Oncology, Inc. on December 12, 2024.

Summary

• Dennis M. McGrath, a director at Citius Oncology, Inc., was granted 125,000 stock options on December 12, 2024.
• These options have an exercise price of $1.07 per share and will vest 100% on the one-year anniversary of the grant date, provided Mr. McGrath continues to provide service to the company.
• Mr. McGrath also holds 150,000 vested stock options with an exercise price of $2.15.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of stock option grants to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Industry Context

Stock option grants to directors are a common practice in publicly traded companies to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, similar to practices at companies like Amgen (AMGN) and Gilead Sciences (GILD).
• The vesting period of one year is also a common practice, aligning with typical industry standards for director compensation.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to better performance and increased shareholder value.

Key Dates

Keywords

stock options, director, insider trading, Cititus Oncology, CTOR, equity, vesting